SC3: The Origins, Optimization and Application of Organ-on-a-Chip Systems
27 NOVEMBER 2018 | 18:00-20:30
This short course will take a more in depth look at the Origins, Optimization and Application of Organ-on-a-Chip Systems. Covering the essential tools and techniques employed in the development and application of Organ-on-a-Chip and MicroPhysiological Systems in more detail. Topics covered will include, the integration of non-biological chips with modern cell culture, microfabrication techniques, 2D and 3D applications, increasing throughput and insuring quality control. Participants can expect to gain a greater understanding of the history and background of Organ-on-a-Chip devices, their current capabilities, current and future industrial applications.
Origins and Basis for Organ- and Human-on-a-Chip Systems
James J. Hickman PhD, Professor, NanoScience Technology Center, University of Central Florida
- How the biological/non-biological interface dominates device fabrication and function
- Tools for building and utilization of these devices
- History and background of the field
- The decision process for 2D vs 3D systems
Increasing Predictivity and Throughput: Chances and Challenges of Organ-on-a-Chip Systems
Peter Loskill PhD, Assistant Professor for Experimental Regenerative Medicine, Dept. of Women’s Health, Research Institute for Women’s Health, Faculty of Medicine, Eberhard Karls University Tübingen
- Discuss chances and limitation of current Organ-on-a-Chip systems
- Evaluate challenges in terms of increase in throughput for Organ-on-a-Chip systems
- Review Concepts for parallelization and automation
- Introduce our novel approach for automated generation of 3D tissues
Fit for Purpose Human Translational Cell Models
Wendy Rowan PhD, FRSB, Associate GSK Fellow, Scientific Leader Target Sciences, GlaxoSmithKline
- Criteria required to qualify models
- Human tissue reference data for model qualification
- Standardizing model qualification criteria to enable cross model comparisons
Instructor Biographies:
James J. Hickman PhD, Professor, NanoScience Technology Center, University of Central Florida
James J. Hickman is the Founding Director of the NanoScience Technology Center and a Professor of Nanoscience Technology, Chemistry, Biomolecular Science, Material Science and Electrical Engineering at the University of Central Florida. Previously, he held the position of the Hunter Endowed Chair in the Bioengineering Department at Clemson University. Dr. Hickman has a Ph.D. from the Massachusetts Institute of Technology in Chemistry. For the past twenty-five years, he has been studying the interaction of biological species with modified surfaces, first in industry and in the latter years in academia. While in industry he established one of the first bioelectronics labs in the country that focused on cell-based sensors and their integration with electronic devices and MEMS devices. He is interested in creating hybrid systems for biosensor and biological computation applications and the creation of functional in vitro systems for human body-on-a-chip applications. He has worked at NSF and DARPA in the area of biological computation. He is also the founder and current Chief Scientist of a biotechnology company, Hesperos, that is focusing on cell-based systems for drug discovery and toxicity. He has 127 publications and 20 book chapters, in addition to 19 issued patents out of 42 total patent applications.
Peter Loskill PhD, Assistant Professor for Experimental Regenerative Medicine, Dept. of Women’s Health, Research Institute for Women’s Health, Faculty of Medicine, Eberhard Karls University Tübingen
Dr. Peter Loskill is Assistant Professor for Experimental Regenerative Medicine at the Eberhard Karls University Tübingen and head of the Fraunhofer Attract group Organ-on-a-Chip at the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB) in Stuttgart, Germany. Dr. Loskill graduated in 2012 from Saarland University with a PhD in Physics focusing on Biointerface science. He then spent three years in the laboratory of Prof. K. E. Healy at the University of California at Berkeley. There, he worked as a postdoctoral fellow and project leader, funded by the NIH NCATS TissueChip program and the German Science Foundation, and developed organ-on-a-chip systems based on human iPS-cell technology. In 2015, he was named as one of Technology Review’s “Innovators under 35 Germany” and was awarded a Fraunhofer ATTRACT Grant, the highest funded German starting grant program, which enabled him to start an independent research group at Fraunhofer IGB. His group focuses on the development of human iPS-cell based, parallelizable microphysiological organ-on-a-chip systems with applications in pharmaceutical research, toxicological screening, and mechanistic studies as well as on the development of enabling technologies that support automation and ease of use of these systems.
Wendy Rowan PhD, FRSB, Associate GSK Fellow, Scientific Leader Target Sciences, GlaxoSmithKline
My science education was spread across a number of London University colleges, including Chelsea (BSc Applied Biology), Birkbeck (MSc Microbiology) and Imperial (PhD: Characterisation of the function of the CD52 antigen on T and B cells). Immunology has been the common theme throughout my career, working on aspects of both innate and adaptive immunity in respiratory and autoimmune diseases.
I am currently employed by GSK. My present role is focussed on target selection and validation for novel therapeutics aimed at modulating epithelial barrier function. In this capacity, I lead a team of cell biologists in the development and application of human disease relevant models for drug discovery. In addition to internal projects, I have established a number of external collaborations to develop and access new human translational cell models. My interest in this area extends to being a core member of the GSK Complex In Vitro Models Matrix team with a remit to identify and evaluate new models for target validation, lead discovery and candidate selection, including safety assessment and PK/PD profiling.